| Q42321604 | A bivalent promoter contributes to stress-induced plasticity of CXCR4 in Ewing sarcoma |
| Q33579422 | A role for the Werner syndrome protein in epigenetic inactivation of the pluripotency factor Oct4. |
| Q39296177 | A shRNA functional screen reveals Nme6 and Nme7 are crucial for embryonic stem cell renewal |
| Q21134097 | Aberrant promoter methylation and expression of UTF1 during cervical carcinogenesis |
| Q27342050 | Aldh1 Expression and Activity Increase During Tumor Evolution in Sarcoma Cancer Stem Cell Populations. |
| Q33275167 | An overview of the role of cancer stem cells in spine tumors with a special focus on chordoma |
| Q26796793 | Autophagy in Cancer Stem Cells: A Potential Link Between Chemoresistance, Recurrence, and Metastasis |
| Q39583314 | BRACHYURY confers cancer stem cell characteristics on colorectal cancer cells |
| Q37287076 | Benign mesenchymal stromal cells in human sarcomas. |
| Q36773026 | Bone marrow mesenchymal stem cells: historical overview and concepts |
| Q38683858 | CANCER STEM CELLS IN OSTEOSARCOMA |
| Q38035206 | CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges |
| Q33546702 | CD133 expression in chemo-resistant Ewing sarcoma cells |
| Q39351454 | CD133 negatively regulates tumorigenicity via AKT pathway in synovial sarcoma |
| Q33908271 | CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres |
| Q35085998 | CD133(+) gallbladder carcinoma cells exhibit self-renewal ability and tumorigenicity |
| Q39473541 | CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor). |
| Q38717895 | CD47: a potential immunotherapy target for eliminating cancer cells |
| Q24642797 | CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis |
| Q58760697 | Calpain-6 controls the fate of sarcoma stem cells by promoting autophagy and preventing senescence |
| Q39773200 | Cancer Stem Cells and Pediatric Solid Tumors |
| Q37841186 | Cancer stem cells and cancer therapy |
| Q28081844 | Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? |
| Q38118769 | Cancer stem cells in pediatric sarcomas |
| Q38476034 | Cancer stem cells: a potential target for cancer therapy |
| Q38211401 | Cancer stem cells: biological functions and therapeutically targeting |
| Q37815127 | Cancer stem cells: problems for therapy? |
| Q33935224 | Characterization of cancer stem-like cells derived from mouse induced pluripotent stem cells transformed by tumor-derived extracellular vesicles |
| Q36200232 | Chemotherapy curable malignancies and cancer stem cells: a biological review and hypothesis |
| Q37855742 | Concise review: mesenchymal tumors: when stem cells go mad. |
| Q36327466 | Congenital Ewing's Sarcoma/Primitive Neuroectodermal Tumor of the Upper Extremity |
| Q33548649 | Constitutive expression of pluripotency-associated genes in mesodermal progenitor cells (MPCs). |
| Q39284675 | Cytogenetically confirmed primary Ewing's sarcoma of the pancreas |
| Q46635839 | Desmoplastic Small Round Blue Cell Tumor: A Review of Treatment and Potential Therapeutic Genomic Alterations. |
| Q39764373 | Differential destruction of stem cells: implications for targeted cancer stem cell therapy |
| Q39120248 | Differential effect of long-term drug selection with doxorubicin and vorinostat on neuroblastoma cells with cancer stem cell characteristics |
| Q38937115 | Differential remodeling of cadherins and intermediate cytoskeletal filaments influence microenvironment of solid and ascitic sarcoma |
| Q26782242 | Differentiation and transdifferentiation potentials of cancer stem cells |
| Q38850277 | Downregulation of cancer stem cell properties via mTOR signaling pathway inhibition by rapamycin in nasopharyngeal carcinoma |
| Q28477091 | Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanisms |
| Q39716224 | EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells |
| Q64103120 | Effect of chemotherapy on cancer stem cells and tumor-associated macrophages in a prospective study of preoperative chemotherapy in soft tissue sarcoma |
| Q35987417 | Endoplasmic reticulum targeting in Ewing's sarcoma by the alkylphospholipid analog edelfosine |
| Q36876146 | Englerin A Inhibits EWS-FLI1 DNA Binding in Ewing Sarcoma Cells |
| Q35790043 | Enrichment of the embryonic stem cell reprogramming factors Oct4, Nanog, Myc, and Sox2 in benign and malignant vascular tumors |
| Q49335412 | Epidermal growth factor receptor aptamer-conjugated polymer-lipid hybrid nanoparticles enhance salinomycin delivery to osteosarcoma and cancer stem cells |
| Q90450797 | Epigenome editing of microsatellite repeats defines tumor-specific enhancer functions and dependencies |
| Q35144825 | Evidence for epithelial-mesenchymal transition in cancer stem-like cells derived from carcinoma cell lines of the cervix uteri |
| Q34992194 | Evidence for label-retaining tumour-initiating cells in human glioblastoma |
| Q33861072 | Ewing Sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions. |
| Q98613150 | Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers |
| Q37012862 | Ewing tumors that do not overexpress BMI-1 are a distinct molecular subclass with variant biology: a report from the Children's Oncology Group |
| Q36177170 | Ewings sarcoma of patella: A rare entity treated with a novel technique of extensor mechanism reconstruction using tendoachilles auto graft |
| Q36375177 | Expression of cancer stem cell markers and their correlation with pathogenesis in vascular tumors |
| Q40695629 | Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas. |
| Q42566287 | Extinction models for cancer stem cell therapy |
| Q28076296 | FOXM1 in sarcoma: role in cell cycle, pluripotency genes and stem cell pathways |
| Q38333689 | FUS-CHOP fusion protein expression coupled to p53 deficiency induces liposarcoma in mouse but not in human adipose-derived mesenchymal stem/stromal cells. |
| Q35989688 | Flow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcoma |
| Q36334761 | Formation of spherical cancer stem-like cell colonies with resistance to chemotherapy drugs in the human malignant fibrous histiocytoma NMFH-1 cell line |
| Q38154988 | G-quadruplexes as potential therapeutic targets for embryonal tumors |
| Q41930875 | HPV-E6 protein enriches the CD55(+) population in cervical cancer cells promoting radio-resistance and cancer aggressiveness |
| Q33750221 | High ALDH Activity Identifies Chemotherapy-Resistant Ewing's Sarcoma Stem Cells That Retain Sensitivity to EWS-FLI1 Inhibition |
| Q39564970 | High CD133 expression levels in gastrointestinal stromal tumors |
| Q39289071 | Human Wharton's jelly stem cell conditioned medium and cell-free lysate inhibit human osteosarcoma and mammary carcinoma cell growth in vitro and in xenograft mice |
| Q35549238 | Hypoxia, stem cells and bone tumor |
| Q35928531 | Identification and Validation of Housekeeping Genes for Gene Expression Analysis of Cancer Stem Cells |
| Q38814109 | Identification and analysis of CXCR4-positive synovial sarcoma-initiating cells |
| Q33921460 | Identification and targeting of cancer stem cells |
| Q38008952 | Identification of cancer stem cells provides novel tumor models for drug discovery |
| Q38212354 | Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective. |
| Q64065740 | Impact of c-MYC expression on proliferation, differentiation, and risk of neoplastic transformation of human mesenchymal stromal cells |
| Q35348175 | Impairment of lysosomal activity as a therapeutic modality targeting cancer stem cells of embryonal rhabdomyosarcoma cell line RD. |
| Q39499299 | In vivo metabolic profiling of glioma-initiating cells using proton magnetic resonance spectroscopy at 14.1 Tesla |
| Q35786713 | Inhibition of Phosphatidylcholine-Specific Phospholipase C Interferes with Proliferation and Survival of Tumor Initiating Cells in Squamous Cell Carcinoma |
| Q39835483 | LGR5 is Expressed by Ewing Sarcoma and Potentiates Wnt/β-Catenin Signaling |
| Q37904866 | Lessons from common markers of tumor-initiating cells in solid cancers |
| Q35958012 | Liposarcoma Cells with Aldefluor and CD133 Activity have a Cancer Stem Cell Potential |
| Q39995715 | Mediastinal mass-a rare presentation of desmoplastic small round cell tumour |
| Q24614044 | Melanoma spheroids grown under neural crest cell conditions are highly plastic migratory/invasive tumor cells endowed with immunomodulator function |
| Q37003304 | Membrane expression of MRP-1, but not MRP-1 splicing or Pgp expression, predicts survival in patients with ESFT. |
| Q34158605 | Mesenchymal stem cell-derived microparticles: a promising therapeutic strategy |
| Q38032086 | Mesenchymal stem cells in tumor development: emerging roles and concepts |
| Q102061308 | Mesenchymal stem/stromal cells: Developmental origin, tumorigenesis and translational cancer therapeutics |
| Q38749818 | Micro-Environmental Stress Induces Src-Dependent Activation of Invadopodia and Cell Migration in Ewing Sarcoma |
| Q36722134 | MicroRNAs in Ewing Sarcoma |
| Q37935534 | Modeling sarcomagenesis using multipotent mesenchymal stem cells |
| Q35957998 | Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours |
| Q33684472 | Mouse models for cancer stem cell research |
| Q37761069 | Nanoparticles: a promising modality in the treatment of sarcomas. |
| Q55429263 | Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells. |
| Q38113988 | Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy |
| Q39099804 | Overcoming Therapeutic Resistance of Bone Sarcomas: Overview of the Molecular Mechanisms and Therapeutic Targets for Bone Sarcoma Stem Cells. |
| Q39823354 | Pathobiologic Markers of the Ewing Sarcoma Family of Tumors: State of the Art and Prediction of Behaviour |
| Q35585820 | Photochemical internalisation, a minimally invasive strategy for light-controlled endosomal escape of cancer stem cell-targeting therapeutics. |
| Q38582873 | Physiological, Tumor, and Metastatic Niches: Opportunities and Challenges for Targeting the Tumor Microenvironment |
| Q38890185 | Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells |
| Q58655582 | Poorly Differentiated Uterine or Cervical Sarcoma in a Young Dog |
| Q36911697 | Potential of herpesvirus saimiri-based vectors to reprogram a somatic Ewing's sarcoma family tumor cell line |
| Q43973145 | Primary Ewing's sarcoma of cranial bones: analysis of ten patients |
| Q34226841 | Quantification of the heterogeneity of prognostic cellular biomarkers in ewing sarcoma using automated image and random survival forest analysis |
| Q55206301 | RETRACTED: Pediatric sarcomas. |
| Q36562720 | Recent advances in the molecular pathogenesis of Ewing's sarcoma |
| Q38852157 | Regulation of Stem Cell Self-Renewal and Oncogenesis by RNA-Binding Proteins. |
| Q34631306 | Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma |
| Q38770102 | Role of Pericellular Matrix in the Regulation of Cancer Stemness |
| Q37993701 | Role of cancer stem cells in spine tumors: review of current literature |
| Q57052668 | STK899704 inhibits stemness of cancer stem cells and migration via the FAK-MEK-ERK pathway in HT29 cells |
| Q42542515 | Salient features of mesenchymal stem cells-implications for Ewing sarcoma modeling |
| Q38015339 | Sarcoma stem cells: do we know what we are looking for? |
| Q48868934 | Self-targeted salinomycin-loaded DSPE-PEG-methotrexate nanomicelles for targeting both head and neck squamous cell carcinoma cancer cells and cancer stem cells |
| Q42906698 | Soft tissue sarcomas: introduction to the Virchows Archiv review issue. |
| Q36424175 | Sphere-forming tumor cells possess stem-like properties in human fibrosarcoma primary tumors and cell lines |
| Q35789091 | Stem cell niche dynamics: from homeostasis to carcinogenesis. |
| Q33925049 | Stem cells and bone diseases: new tools, new perspective |
| Q33275229 | Surgical treatment of sarcomas of the spine |
| Q35458552 | Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma |
| Q39719445 | TEThered to Runx: novel binding partners for runx factors |
| Q28076462 | Targeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and Treatment |
| Q90429907 | Targeting DNA Hypomethylation in Malignancy by Epigenetic Therapies |
| Q48110212 | Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma. |
| Q37820099 | Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways |
| Q34335524 | Targeting the osteosarcoma cancer stem cell |
| Q39674655 | The Ewing's sarcoma fusion protein, EWS-FLI, binds Runx2 and blocks osteoblast differentiation. |
| Q39622263 | The HPB-AML-I cell line possesses the properties of mesenchymal stem cells |
| Q39389679 | The MET oncogene transforms human primary bone-derived cells into osteosarcomas by targeting committed osteo-progenitors |
| Q38254181 | The cancer stem cell hypothesis: a guide to potential molecular targets |
| Q35993560 | The first European interdisciplinary ewing sarcoma research summit |
| Q42366629 | The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells |
| Q39564395 | The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2. |
| Q38896944 | The hypoxic microenvironment: A determinant of cancer stem cell evolution |
| Q36538487 | The implications of cancer stem cells for cancer therapy |
| Q42177224 | The molecular biology of soft-tissue sarcomas and current trends in therapy |
| Q89467746 | The role of CD133 in cancer: a concise review |
| Q37043780 | The role of mesenchymal stem/progenitor cells in sarcoma: update and dispute |
| Q33559711 | The therapeutic promise of the cancer stem cell concept |
| Q34220071 | Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line |
| Q34159047 | Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton |
| Q37548863 | Treatment of agarose-agarose RENCA macrobeads with docetaxel selects for OCT4(+) cells with tumor-initiating capability |
| Q33894449 | Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus. |
| Q34156000 | Tumor-initiating cells are rare in many human tumors |
| Q37608149 | Widespread Chromatin Accessibility at Repetitive Elements Links Stem Cells with Human Cancer |
| Q53311529 | [Tumor stem cell research - basis and challenge for diagnosis and therapy]. |
| Q39465507 | miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy |